ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
AIM ImmunoTech Inc

AIM ImmunoTech Inc (HXB2)

0.222
0.00
( 0.00% )
Updated: 06:35:39
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.222
Bid
0.216
Ask
0.226
Volume
0.00
0.00 Day's Range 0.00
0.178 52 Week Range 0.60
Previous Close
0.222
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
6,218
Financial Volume
-
VWAP
-

HXB2 Latest News

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue OCALA, Fla., Dec. 12, 2024 (GLOBE...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.02915.02590673580.1930.220.193101630.21340068DE
40.02713.84615384620.1950.2460.18357080.20660746DE
12-0.024-9.756097560980.2460.2460.17862180.20677648DE
26-0.112-33.53293413170.3340.3520.17854470.23500253DE
52-0.17-43.36734693880.3920.60.17843690.29223966DE
156-0.3429999-60.70795764740.56499990.610.17840290.32498482DE
260-0.3429999-60.70795764740.56499990.610.17840290.32498482DE

HXB2 - Frequently Asked Questions (FAQ)

What is the current AIM ImmunoTech share price?
The current share price of AIM ImmunoTech is 0.222 €
What is the 1 year trading range for AIM ImmunoTech share price?
AIM ImmunoTech has traded in the range of 0.178 € to 0.60 € during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HPMHorizon Petroleum Ltd
0.165 €
(41.03%)
228.05k
H7KPeak Minerals Limited
0.009 €
(38.46%)
5k
AAHAhlers AG
0.011 €
(37.50%)
3k
RXK3SELLAS Life Sciences Group Inc
1.428 €
(29.82%)
1,000
L7C2Windfall Geotek Inc
0.011 €
(29.41%)
1.37k
SL5Recharge Resources Ltd
0.0208 €
(-41.24%)
500
YBBCarnavale Resources Ltd
0.002 €
(-33.33%)
75.17k
M000Vertical Aerospace Ltd
6.15 €
(-30.90%)
6.45k
PA8Paion AG
0.0152 €
(-29.63%)
438
K1SNKlondike Silver Corporation
0.007 €
(-26.32%)
1.5k
PF8European Lithium Limited
0.0352 €
(-12.87%)
7.87M
W1HOnco Innovations Limited
1.428 €
(18.02%)
1.34M
D7GNel ASA
0.1907 €
(-0.21%)
1.32M
432Arbor Metals Corp
0.3595 €
(14.49%)
1.2M
HDDHeidelberger Druckmaschinen AG
1.194 €
(5.48%)
935.38k

Discussion

View Full Feed
Zardiw Zardiw 5 minutes ago
Why so mean? Not a good thing to have in your brain. You should keep a leash on that Ego monster you got there. Only thing that can do that is the Holy Spirit inside you.........

Z
BLBX
Here Today Here Today 5 minutes ago
Many will be left with mere scraps as far as share count goes, while some will be slowly selling off their 18+ million shares riding off into the sunset.  And there will also be others who will still be gleefully talking about their beer money they made.....
VDRM
mascale mascale 5 minutes ago
So among the literate, "No Response" is itself actual data. Failing to report the category is "Data-free."
HIRU
bucks2pennies bucks2pennies 6 minutes ago
Oh well, not this week either....
GTCH
Monksdream Monksdream 7 minutes ago
Top 15 at 8:00
Slow very slow

https://ih.advfn.com/markets/nasdaq/premarket
lovingit lovingit 7 minutes ago
Supervisor from TD Brokerage reached out to the trading desk and the person confirmed it is not halted, I'm so confused getting mixed signals, we'll have to wait until the market opens to see what happens to know for sure.
TWOH
TheDane TheDane 7 minutes ago
A governing board of experts is the last thing anyone needs. Unless they’re all saints.
IONQ
Here Today Here Today 8 minutes ago
Slaps of millions upon millions in share volumes will occur driving the PPS higher $.05 at a time......
VDRM
BlazingStocks BlazingStocks 8 minutes ago
$COEP News January 07, 2025

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform
https://finance.yahoo.com/news/coeptis-therapeutics-announces-first-customer-130000003.html
COEP
CanItBThisEZ2Make CanItBThisEZ2Make 8 minutes ago
BEST SELLERS RANK (BSR) IS 374 17 Estimated Sold on Amazon Since JAN 1 - 1ST Quarter 2025
https://investorshub.advfn.com/uimage/uploads/2024/4/24/cnxttVOS_5G_GIF.gif
https://www.amazon.com/Vos-RDGL5GX55-B-01-VOS-5G-Dongle/dp/B0C66KHZLP

NOTE: In theory, when BSR Value Dec
SRMX
glenn1919 glenn1919 8 minutes ago
MDAI......MBOT........VERU.........BNZI.........MULN.................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134
BNZI MBOT MDAI
georgie18 georgie18 8 minutes ago
GNPX...76...Added on News...🥳...https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html

georgie1
GNPX
georgie18 georgie18 8 minutes ago
GNPX...76...Added on News...🥳...https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html

georgie1
GNPX
dexprs dexprs 8 minutes ago
Looking at the Put Call Ratio, I see that the smart money is looking for a pull back as they were buying Puts a little below the recent highs in the technology sector and the large caps that ran up the most.
I will taper my planned purchases by 1/3.
The 10YT yield is heading up slowly
nowwhat2 nowwhat2 9 minutes ago
https://investorshub.advfn.com/uimage/uploads/2025/1/22/gxmfybtc_!_22_capt_8pm_WT_MAGIC.jpg

https://investorshub.advfn.com/uimage/uploads/2025/1/22/jdzuyBTC_!_22_1M_6pm_100k_ON_DIAG.jpg


https://investorshub.advfn.com/uimage/uploads/2025/1/22/ulhfvBTC_!_22_1M_612
BTCUSD
georgie18 georgie18 9 minutes ago
GNPX...76...Added on News...🥳...https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html

georgie1
GNPX
georgejjl georgejjl 9 minutes ago
News next week regarding a new potentially pivotal trial for treatment of Parkinson’s disease with Anavex’s blarcamesine.

Good luck and GOD bless,
AVXL
wadegarret wadegarret 9 minutes ago
updated

GERN 70000 shares

Cash $35764
GERN
budfoxfun budfoxfun 9 minutes ago
The television advertising will showcase SGTM's brand on major networks such as ESPN2, THE DISCOVERY CHANNEL, PURSUIT NETWORK, WFN, ATT SPORTS SW, and other networks as they become available.
SGTM
LandPro LandPro 10 minutes ago
With No substance, no communication, and no game plan, I highly doubt these slant-eyed scamming communist chinamen can pull off another pump and dump. Even the real pumpers are MIA. There are zero reasons to buy this garbage, which is obvious. FFS😆
IGPK
Real McCoy Real McCoy 10 minutes ago
This is dead, right? Liquidation 6 years ago?
joe_techi joe_techi 10 minutes ago
“For so long, people were like, ‘You can't do work in pain, because everything fails,’” CBO James Hackworth, told Fierce. “Now, after decades of nothing new, it looks like we're on the cusp of two things that are very new that will succeed.”

Tris Pharma's alternative to opioids reduce
NPHC
bones jones bones jones 10 minutes ago
It is halted
https://www.otcmarkets.com/stock/TWOH/security

TWOH
budfoxfun budfoxfun 10 minutes ago
A key product in SGTM's portfolio, HumiSoil is a patented formula invented by VRM Biologik designed to replenish organic nutrients and water solubility in depleted soils. In today's agricultural practices, soil often loses vital nutrients, leading to reduced crop yields and hampering carbon dioxide
SGTM
ANTI-BAGHOLDER ANTI-BAGHOLDER 10 minutes ago
You were the one pumping "contracts".  Than you went silent about it.

Funny how that works. 
MONI